HN2003000090A - Compuestos que modulan la actividad de ppar - Google Patents

Compuestos que modulan la actividad de ppar

Info

Publication number
HN2003000090A
HN2003000090A HN2003000090A HN2003000090A HN2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A
Authority
HN
Honduras
Prior art keywords
ppar
modulate
activity
compounds
formulations
Prior art date
Application number
HN2003000090A
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Quano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN2003000090A publication Critical patent/HN2003000090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS Y FORMULACIONES FARMACEUTICAS QUE PUEDEN UTILIZARSE PARA TRATAR AFECCIONES INDUCIDAS POR RECEPTORES HORMONALES NUCLEARES, MAS ESPECIFICAMENTE, A COMPUESTOS Y FORMULACIONES FARMACEUTICAS QUE MODULAN LA ACTIVIDAD DE PPAR.
HN2003000090A 2002-03-07 2003-03-06 Compuestos que modulan la actividad de ppar HN2003000090A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
HN2003000090A true HN2003000090A (es) 2004-05-05

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000090A HN2003000090A (es) 2002-03-07 2003-03-06 Compuestos que modulan la actividad de ppar

Country Status (29)

Country Link
US (1) US20030207924A1 (es)
EP (1) EP1482935B1 (es)
JP (1) JP2005528348A (es)
KR (1) KR20040091693A (es)
AP (1) AP2004003124A0 (es)
AR (1) AR038881A1 (es)
AT (1) ATE405260T1 (es)
AU (1) AU2003206059A1 (es)
BR (1) BR0308277A (es)
CA (1) CA2478520A1 (es)
CO (1) CO5601012A2 (es)
DE (1) DE60323060D1 (es)
EA (1) EA200400943A1 (es)
EC (1) ECSP045285A (es)
ES (1) ES2310650T3 (es)
HN (1) HN2003000090A (es)
IS (1) IS7377A (es)
MA (1) MA27181A1 (es)
MX (1) MXPA04007564A (es)
NO (1) NO20044242L (es)
OA (1) OA12780A (es)
PA (1) PA8567801A1 (es)
PE (1) PE20030989A1 (es)
PL (1) PL372969A1 (es)
TN (1) TNSN04168A1 (es)
TW (1) TW200305403A (es)
UY (1) UY27695A1 (es)
WO (1) WO2003074050A1 (es)
ZA (1) ZA200406068B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1638551B1 (en) * 2003-05-19 2011-12-21 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
WO2006121223A1 (en) * 2005-05-07 2006-11-16 Heon Joong Kang Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
AU2006265172B2 (en) 2005-06-30 2011-09-15 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
JP5084503B2 (ja) * 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
WO2008130514A1 (en) 2007-04-16 2008-10-30 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
WO2009078981A2 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
BR112012021515A2 (pt) * 2010-02-25 2016-07-05 Snu R&Db Foundation derivado de selenazol tendo ligantes os quais ativam o receptor ativado de proliferador de peroxissomo (ppar), método de preparação do mesmo e o uso dos compostos químicos
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
CZ53699A3 (cs) * 1996-08-19 1999-07-14 Japan Tobacco Inc. Deriváty propionové kyseliny a jejich použití
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2002050047A1 (en) * 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
HUP0400268A2 (hu) * 2001-06-07 2004-07-28 Eli Lilly And Co. Peroxiszóma proliferátorral aktivált receptorokat (PPAR) módosító hatóanyagok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
KR20040091693A (ko) 2004-10-28
DE60323060D1 (de) 2008-10-02
PA8567801A1 (es) 2003-11-12
ES2310650T3 (es) 2009-01-16
PL372969A1 (en) 2005-08-08
NO20044242L (no) 2004-10-06
EP1482935A1 (en) 2004-12-08
MA27181A1 (fr) 2005-01-03
JP2005528348A (ja) 2005-09-22
ZA200406068B (en) 2005-09-06
ECSP045285A (es) 2004-10-26
TNSN04168A1 (fr) 2007-03-12
WO2003074050A1 (en) 2003-09-12
CA2478520A1 (en) 2003-09-12
AR038881A1 (es) 2005-02-02
OA12780A (en) 2006-07-07
AU2003206059A1 (en) 2003-09-16
US20030207924A1 (en) 2003-11-06
AP2004003124A0 (en) 2004-09-30
IS7377A (is) 2004-07-29
MXPA04007564A (es) 2004-11-10
CO5601012A2 (es) 2006-01-31
EA200400943A1 (ru) 2005-02-24
TW200305403A (en) 2003-11-01
PE20030989A1 (es) 2003-11-29
UY27695A1 (es) 2003-10-31
BR0308277A (pt) 2004-12-28
EP1482935B1 (en) 2008-08-20
ATE405260T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
HN2003000090A (es) Compuestos que modulan la actividad de ppar
HN2003000113A (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
NI200300039A (es) Compuestos que modulan la actividad de ppar.
UY27704A1 (es) Compuestos que modulan la actividad de ppar
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
SV2003001493A (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
BRPI0517088A (pt) formulação de comprimido estável
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
CR8926A (es) Acidos de tiazolo-naftilo
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
GT200100199A (es) Nuevos retinoides para el tratamiento de efisema.
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
HN2003000208A (es) Estructura perfeccionada de suela impermeable y transpirante para calzados
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo